Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to represent a notable development for obesity treatment. Initial human investigations have demonstrated impressive reductions in abdominal fat , possibly exceeding other weight-loss medications . However , additiona